{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:58:56Z","timestamp":1768679936488,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41417-020-0161-3","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:04:15Z","timestamp":1580169855000},"page":"869-877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0417-2147","authenticated-orcid":false,"given":"Zhongqing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxing","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongrong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"161_CR1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood-2018-11-877795","volume":"133","author":"H Avet-Loiseau","year":"2019","unstructured":"Avet-Loiseau H. Introduction to a review series on advances in multiple myeloma. Blood 2019;133:621.","journal-title":"Blood"},{"key":"161_CR2","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2009-01-198408","volume":"113","author":"AM Roccaro","year":"2009","unstructured":"Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669\u201380.","journal-title":"Blood"},{"key":"161_CR3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203\u201322.","journal-title":"Nat Rev Drug Discov"},{"key":"161_CR4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drudis.2017.09.018","volume":"23","author":"PH Hagedorn","year":"2018","unstructured":"Hagedorn PH, Persson R, Funder ED, Albaek N, Diemer SL, Hansen DJ, et al. Locked nucleic acid: modality, diversity, and drug discovery. Drug Discov Today. 2018;23:101\u201314.","journal-title":"Drug Discov Today"},{"key":"161_CR5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.drudis.2017.01.013","volume":"22","author":"X Chi","year":"2017","unstructured":"Chi X, Gatti P, Papoian T. Safety of antisense oligonucleotide and siRNA-based therapeutics. Drug Discov Today. 2017;22:823\u201333.","journal-title":"Drug Discov Today"},{"key":"161_CR6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"161_CR7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","volume":"70","author":"CF Bennett","year":"2019","unstructured":"Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019;70:307\u201321.","journal-title":"Annu Rev Med"},{"key":"161_CR8","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/cncr.26297","volume":"118","author":"L Benetatos","year":"2012","unstructured":"Benetatos L, Vartholomatos G. Deregulated microRNAs in multiple myeloma. Cancer 2012;118:878\u201387.","journal-title":"Cancer"},{"key":"161_CR9","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1002\/jcp.27342","volume":"234","author":"T Liu","year":"2019","unstructured":"Liu T, Xu Z, Ou D, Liu J, Zhang J. The miR-15a\/16 gene cluster in human cancer: a systematic review. J Cell Physiol. 2019;234:5496\u2013506.","journal-title":"J Cell Physiol"},{"key":"161_CR10","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/ijc.29199","volume":"136","author":"M Hao","year":"2015","unstructured":"Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, et al. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2015;136:1835\u201344.","journal-title":"Int J Cancer"},{"key":"161_CR11","doi-asserted-by":"crossref","first-page":"38270","DOI":"10.18632\/oncotarget.5681","volume":"6","author":"F Li","year":"2015","unstructured":"Li F, Xu Y, Deng S, Li Z, Zou D, Yi S, et al. MicroRNA-15a\/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma. Oncotarget 2015;6:38270\u201382.","journal-title":"Oncotarget"},{"key":"161_CR12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.leukres.2015.04.010","volume":"39","author":"F Li","year":"2015","unstructured":"Li F, Hao M, Feng X, Zang M, Qin Y, Yi S, et al. Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. Leuk Res 2015;39:793\u20139.","journal-title":"Leuk Res"},{"key":"161_CR13","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3109\/10428194.2011.576791","volume":"52","author":"M Hao","year":"2011","unstructured":"Hao M, Zhang L, An G, Meng H, Han Y, Xie Z, et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk lymphoma. 2011;52:1787\u201394.","journal-title":"Leuk lymphoma"},{"key":"161_CR14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1756-8722-4-37","volume":"4","author":"M Hao","year":"2011","unstructured":"Hao M, Zhang L, An G, Sui W, Yu Z, Zou D, et al. Suppressing miRNA-15a\/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol. 2011;4:37.","journal-title":"J Hematol Oncol"},{"key":"161_CR15","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/jcb.26294","volume":"119","author":"J Shi","year":"2018","unstructured":"Shi J, Fu Q, Yang P, Liu H, Ji L, Wang K. Downregulation of microRNA-15a-3p is correlated with clinical outcome and negatively regulates cancer proliferation and migration in human osteosarcoma. J Cell Biochem. 2018;119:1215\u201322.","journal-title":"J Cell Biochem"},{"key":"161_CR16","first-page":"2655","volume":"15","author":"L Liu","year":"2018","unstructured":"Liu L, Wang D, Qiu Y, Dong H, Zhan X. Overexpression of microRNA-15 increases the chemosensitivity of colon cancer cells to 5-fluorouracil and oxaliplatin by inhibiting the nuclear factor-kappaB signalling pathway and inducing apoptosis. Exp Ther Med. 2018;15:2655\u201360.","journal-title":"Exp Ther Med"},{"key":"161_CR17","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.3892\/or.2017.5901","volume":"38","author":"G Li","year":"2017","unstructured":"Li G, Chong T, Xiang X, Yang J, Li H. Downregulation of microRNA-15a suppresses the proliferation and invasion of renal cell carcinoma via direct targeting of eIF4E. Oncol Rep 2017;38:1995\u20132002.","journal-title":"Oncol Rep"},{"key":"161_CR18","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.sjbs.2017.11.028","volume":"24","author":"J He","year":"2017","unstructured":"He J. Knocking down MiR-15a expression promotes the occurrence and development and induces the EMT of NSCLC cells in vitro. Saudi J Biol Sci. 2017;24:1859\u201365.","journal-title":"Saudi J Biol Sci"},{"key":"161_CR19","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1007\/s13277-015-4427-6","volume":"37","author":"J Long","year":"2016","unstructured":"Long J, Jiang C, Liu B, Fang S, Kuang M. MicroRNA-15a-5p suppresses cancer proliferation and division in human hepatocellular carcinoma by targeting BDNF. Tumour Biol. 2016;37:5821\u20138.","journal-title":"Tumour Biol"},{"key":"161_CR20","doi-asserted-by":"crossref","first-page":"13941","DOI":"10.1007\/s13277-016-5271-z","volume":"37","author":"C Alderman","year":"2016","unstructured":"Alderman C, Sehlaoui A, Xiao Z, Yang Y. MicroRNA-15a inhibits the growth and invasiveness of malignant melanoma and directly targets on CDCA4 gene. Tumour Biol. 2016;37:13941\u201350.","journal-title":"Tumour Biol"},{"key":"161_CR21","doi-asserted-by":"crossref","first-page":"15093","DOI":"10.18632\/oncotarget.7618","volume":"7","author":"SK Dwivedi","year":"2016","unstructured":"Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, et al. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget 2016;7:15093\u2013104.","journal-title":"Oncotarget"},{"key":"161_CR22","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2017.115","volume":"31","author":"M Hao","year":"2017","unstructured":"Hao M, Franqui-Machin R, Xu H, Shaughnessy J Jr., Barlogie B, Roodman D, et al. NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma. Leukemia 2017;31:1648\u201350.","journal-title":"Leukemia"},{"key":"161_CR23","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1172\/JCI98765","volume":"128","author":"R Franqui-Machin","year":"2018","unstructured":"Franqui-Machin R, Hao M, Bai H, Gu Z, Zhan X, Habelhah H, et al. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Investig. 2018;128:2877\u201393.","journal-title":"J Clin Investig"},{"key":"161_CR24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1158\/1078-0432.CCR-18-1435","volume":"25","author":"M Hao","year":"2019","unstructured":"Hao M, Barlogie B, Tricot G, Liu L, Qiu L, Shaughnessy JD Jr., et al. Gene expression profiling reveals aberrant T-cell marker expression on tumor cells of Waldenstrom\u2019s macroglobulinemia. Clin Cancer Res. 2019;25:201\u20139.","journal-title":"Clin Cancer Res"},{"key":"161_CR25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-019-0723-8","volume":"12","author":"Y Yang","year":"2019","unstructured":"Yang Y, Zhang X, Lin F, Xiong M, Fan D, Yuan X, et al. Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells. J Hematol Oncol. 2019;12:46.","journal-title":"J Hematol Oncol"},{"key":"161_CR26","doi-asserted-by":"crossref","unstructured":"Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, et al. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-mir-17-92. Blood. 2018;132:1050\u20131063.","DOI":"10.1182\/blood-2018-03-836601"},{"key":"161_CR27","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s13277-015-3950-9","volume":"37","author":"V Bozok Cetintas","year":"2016","unstructured":"Bozok Cetintas V, Tetik Vardarli A, Duzgun Z, Tezcanli Kaymaz B, Acikgoz E, Aktug H, et al. miR-15a enhances the anticancer effects of cisplatin in the resistant non-small cell lung cancer cells. Tumour Biol. 2016;37:1739\u201351.","journal-title":"Tumour Biol"},{"key":"161_CR28","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1158\/0008-5472.CAN-10-4645","volume":"71","author":"AF Ibrahim","year":"2011","unstructured":"Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011;71:5214\u201324.","journal-title":"Cancer Res"},{"key":"161_CR29","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/mt.2011.48","volume":"19","author":"P Trang","year":"2011","unstructured":"Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011;19:1116\u201322.","journal-title":"Mol Ther"},{"key":"161_CR30","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1158\/0008-5472.CAN-12-2001","volume":"72","author":"AL Kasinski","year":"2012","unstructured":"Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 2012;72:5576\u201387.","journal-title":"Cancer Res"},{"key":"161_CR31","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3427","volume":"4","author":"CV Pecot","year":"2013","unstructured":"Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, et al. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013;4:2427.","journal-title":"Nat Commun"},{"key":"161_CR32","first-page":"1287","volume":"15","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zhou L, Shi M, Kuang Y, Fang L. Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression. Oncol Lett. 2018;15:1287\u201396.","journal-title":"Oncol Lett"},{"key":"161_CR33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/cdd.2017.159","volume":"25","author":"Y Pekarsky","year":"2018","unstructured":"Pekarsky Y, Balatti V, Croce CM. BCL2 and miR-15\/16: from gene discovery to treatment. Cell Death Differ. 2018;25:21\u201326.","journal-title":"Cell Death Differ"},{"key":"161_CR34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/carcin\/bgs333","volume":"34","author":"CY Sun","year":"2013","unstructured":"Sun CY, She XM, Qin Y, Chu ZB, Chen L, Ai LS, et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis 2013;34:426\u201335.","journal-title":"Carcinogenesis"},{"key":"161_CR35","doi-asserted-by":"crossref","first-page":"43690","DOI":"10.1074\/jbc.M111.290437","volume":"286","author":"I Sambri","year":"2011","unstructured":"Sambri I, Capasso R, Pucci P, Perna AF, Ingrosso D. The microRNA 15a\/16-1 cluster down-regulates protein repair isoaspartyl methyltransferase in hepatoma cells: implications for apoptosis regulation. J Biol Chem. 2011;286:43690\u2013700.","journal-title":"J Biol Chem"},{"key":"161_CR36","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0760-x","volume":"17","author":"P Utaijaratrasmi","year":"2018","unstructured":"Utaijaratrasmi P, Vaeteewoottacharn K, Tsunematsu T, Jamjantra P, Wongkham S, Pairojkul C, et al. The microRNA-15a-PAI-2 axis in cholangiocarcinoma-associated fibroblasts promotes migration of cancer cells. Mol Cancer 2018;17:10.","journal-title":"Mol Cancer"},{"key":"161_CR37","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.7314\/APJCP.2014.15.16.6949","volume":"15","author":"P Li","year":"2014","unstructured":"Li P, Xie XB, Chen Q, Pang GL, Luo W, Tu JC, et al. MiRNA-15a mediates cell cycle arrest and potentiates apoptosis in breast cancer cells by targeting synuclein-gamma. Asian Pac J Cancer Prev 2014;15:6949\u201354.","journal-title":"Asian Pac J Cancer Prev"},{"key":"161_CR38","first-page":"706","volume":"23","author":"K Zhao","year":"2015","unstructured":"Zhao K, Zhan R, Wu SQ, Huang HB, Xu ZZ, Niu WY. Growth inhibition of multiple myeloma cells caused by microRNA-15a and its mechanisms. Zhongguo shi Yan Xue Ye Xue Za Zhi. 2015;23:706\u201312.","journal-title":"Zhongguo shi Yan Xue Ye Xue Za Zhi"},{"key":"161_CR39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.leukres.2016.08.013","volume":"49","author":"Y Li","year":"2016","unstructured":"Li Y, Zhang B, Li W, Wang L, Yan Z, Li H, et al. MiR-15a\/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma. Leuk Res 2016;49:73\u20139.","journal-title":"Leuk Res"},{"key":"161_CR40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0165-022X(86)90021-7","volume":"13","author":"E Wickstrom","year":"1986","unstructured":"Wickstrom E. Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods. 1986;13:97\u2013102.","journal-title":"J Biochem Biophys Methods"},{"key":"161_CR41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/aian.AIAN_349_17","volume":"21","author":"A Verma","year":"2018","unstructured":"Verma A. Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases. Ann Indian Acad Neurol. 2018;21:3\u20138.","journal-title":"Ann Indian Acad Neurol"},{"key":"161_CR42","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1128\/AAC.00222-11","volume":"55","author":"C Laxton","year":"2011","unstructured":"Laxton C, Brady K, Moschos S, Turnpenny P, Rawal J, Pryde DC, et al. Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site. Antimicrob Agents Chemother. 2011;55:3105\u201314.","journal-title":"Antimicrob Agents Chemother"},{"key":"161_CR43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","volume":"134","author":"A Chari","year":"2019","unstructured":"Chari A, Martinez-Lopez J, Mateos MV, Blade J, Benboubker L, Oriol A, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 2019;134:421\u201331.","journal-title":"Blood"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41417-020-0161-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-020-0161-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-020-0161-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:10:50Z","timestamp":1684617050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-020-0161-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["161"],"URL":"https:\/\/doi.org\/10.1038\/s41417-020-0161-3","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]},"assertion":[{"value":"9 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}